169 related articles for article (PubMed ID: 37952541)
41. Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after retrospective cohort study.
Arrossi S; Paolino M; Laudi R; Gago J; Campanera A; Marín O; Falcón C; Serra V; Herrero R; Thouyaret L
Lancet Glob Health; 2019 Jun; 7(6):e772-e783. PubMed ID: 31097279
[TBL] [Abstract][Full Text] [Related]
42. Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection.
Jones J; Saleem A; Rai N; Shylasree TS; Ashman S; Gregory K; Powell N; Tristram A; Fiander A; Hibbitts S
J Clin Virol; 2011 Oct; 52(2):88-92. PubMed ID: 21831706
[TBL] [Abstract][Full Text] [Related]
43. Risk factors analysis of recurrent disease after treatment with a loop electrosurgical excision procedure for high-grade cervical intraepithelial neoplasia.
Ding T; Li L; Duan R; Chen Y; Yang B; Xi M
Int J Gynaecol Obstet; 2023 Feb; 160(2):538-547. PubMed ID: 35810389
[TBL] [Abstract][Full Text] [Related]
44. Risk of Cervical Dysplasia After Colposcopy Care and Risk-Informed Return to Population-Based Screening: A Systematic Review.
Costa-Fagbemi M; Yakubu M; Meggetto O; Moffatt J; Walker MJ; Koné AP; Murphy KJ; Kupets R
J Obstet Gynaecol Can; 2020 May; 42(5):607-624. PubMed ID: 31679914
[TBL] [Abstract][Full Text] [Related]
45. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.
Isidean SD; Mayrand MH; Ramanakumar AV; Gilbert L; Reid SL; Rodrigues I; Ferenczy A; Ratnam S; Coutlée F; Franco EL;
Int J Cancer; 2016 Dec; 139(11):2456-66. PubMed ID: 27538188
[TBL] [Abstract][Full Text] [Related]
46. Human papilloma virus testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia.
Almog B; Gamzu R; Kuperminc MJ; Levin I; Fainaru O; Niv J; Bar-Am A
Gynecol Oncol; 2003 Mar; 88(3):345-50. PubMed ID: 12648585
[TBL] [Abstract][Full Text] [Related]
47. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization.
Gosvig CF; Huusom LD; Andersen KK; Duun-Henriksen AK; Frederiksen K; Iftner A; Svare E; Iftner T; Kjaer SK
Int J Cancer; 2015 Dec; 137(12):2927-33. PubMed ID: 26139420
[TBL] [Abstract][Full Text] [Related]
48. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study.
Kocken M; Helmerhorst TJ; Berkhof J; Louwers JA; Nobbenhuis MA; Bais AG; Hogewoning CJ; Zaal A; Verheijen RH; Snijders PJ; Meijer CJ
Lancet Oncol; 2011 May; 12(5):441-50. PubMed ID: 21530398
[TBL] [Abstract][Full Text] [Related]
49. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
50. [The role of HPV genotyping testing in follow-up of high grade squamous intraepithelial lesion after treatment].
Li N; Zuo J; Huang Y; An J; Yao H; Li X; Zhang R; Li B; Zhang X; Guo H; Wu L
Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):258-62. PubMed ID: 26080936
[TBL] [Abstract][Full Text] [Related]
51. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
52. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
[TBL] [Abstract][Full Text] [Related]
53. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.
Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Garcia S; Campo E; Pahisa J; Ordi J
Am J Obstet Gynecol; 2007 Oct; 197(4):359.e1-6. PubMed ID: 17714678
[TBL] [Abstract][Full Text] [Related]
54. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
55. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
[TBL] [Abstract][Full Text] [Related]
56. Extended HPV Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2/3 or Worse in a Cohort Study.
Li X; Rao X; Wei MJ; Lu WG; Xie X; Wang XY
J Natl Compr Canc Netw; 2022 Aug; 20(8):906-914.e10. PubMed ID: 35948040
[TBL] [Abstract][Full Text] [Related]
57. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
58. Risk of cervical intraepithelial neoplasia grade 2 or worse in women aged ≥ 69 referred to colposcopy due to an HPV-positive screening test.
Booth BB; Tranberg M; Gustafson LW; Christiansen AG; Lapirtis H; Krogh LM; Hjorth IMD; Hammer A
BMC Cancer; 2023 May; 23(1):405. PubMed ID: 37142959
[TBL] [Abstract][Full Text] [Related]
59. Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results.
Cohen D; Austin RM; Gilbert C; Freij R; Zhao C
Am J Clin Pathol; 2012 Oct; 138(4):517-23. PubMed ID: 23010706
[TBL] [Abstract][Full Text] [Related]
60. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
